Therapy for primary mediastinal large B-cell lymphoma in accordance with the R-DA-EPOCH-21 program: The first results


Cite item

Full Text

Abstract

Aim. To evaluate the efficiency of the R-DA-EPOCH-21 + R-DHAP protocol and autologous hematopoietic stem cell transplantation (a BEAM conditioning mode) in first-line therapy for primary mediastinal large B-cell lymphoma (PMBCL). Subjects and methods. In 2013 to 2016, the investigation enrolled 57 patients with newly diagnosed PMBCL (according to the 2008 WHO criteria). The results were analyzed in 40 patients who had completed their treatment. Results. All the 40 patients (14 men and 26 women) (median age, 27 years (19 to 67 years)) received 6 cycles of polychemotherapy (PCT) in accordance with the R-DA-EPOCH-21 regimen. After induction PCT cycles, 32/40 (80%) patients achieved complete remission. Partial remission was stated in 8/40 (20%) patients who had further 2 cycles of chemotherapy using the R-DHAP program and autologous hematopoietic stem cell transplantation (a BEAM conditioning mode). Two-year overall and relapse-free survival rates were 100% and 96%, respectively; the median follow-up was 17 months. Conclusion. The R-DA-EPOCH regimen allows complete remission in 80% of the cases and two-year survival in 100%. If there are unfavorable factors at onset and in partial remission, it is appropriate to intensify treatment at early stages, by using high-dose chemotherapy and autologous hematopoietic stem transplantation.

References

  1. Lichtenstein AK, Levine A, Taylor CR, Boswell W, Rossman S, Feinstein DI, Lukes RJ. Primary mediastinal lymphoma in adults. Am J Med. 1980;68:509-514. doi: 10.1016/0002-343(80)90294-6
  2. Savage KJ. Primary Mediastinal Large B-Cell Lymphoma. Oncologist 2006;11:488-495. doi: 10.1634/theoncologist.11-5-488
  3. Lazzarino M, Orlandi E, Pauli M, Boveri E, Morra E, Brusamolino E, Kindl S, Rosso R, Astori C, Buonanno MC. Primary mediastinal B-cell lymphoma with sclerosis: An aggressive tumor with distinctive clinical and pathologic features. Clin Oncol. 1993;11:2306-2313. doi: 10.3109/10428199709058608
  4. Fisher SG, Fisher RI. The epidemiology of non-Hodgkin lymphoma. Oncogene. 2004;23:6524-6534. doi: 10.1038/sj.onc.1207843
  5. Hofmann WJ, Momburg F, Moller P, Otto HF. Intra-and extrathymus B-cell in physiologic conditions: Immunohistochemical study of normal thymus and hyperplasia of the thymus. Verchows Arch A Pathol Ana. Histopathol. 413:431. doi: 10.1007/bf00750577
  6. Steidl C, Gascoyne R. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659-2669. doi: 10.1182/blood-2011-05-326538
  7. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan WC, Zhao T, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E, Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink K, Connors JM, Braziel R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M, Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD, Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198(6):851-862. doi: 10.1084/jem.20031074
  8. Rodriguez J, Pugh WC, Romaguera JE, Cabanillas R. Primary mediastinal large cell lymphoma. Hematol Oncol. 1994;12:175-184. doi: 10.1002/hon.2900120404
  9. Zinzani PL, Fanti S, Battista G,Tani M, Castellucci P, Stefoni V, Alinari L, Farsad M, Musuraca G, Gabriele A, Marchi E, Nanni C, Canini R, Monetti N, Baccarani M. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer. 2004;91:850-854. doi: 10.1038/sj.bjc.6602040
  10. Barth TF, Leithauser F, Joos S, Bentz M, Moller P. Mediastinal (thymic) large B-cell lymphoma: where do we stand? Lancet Oncol. 2002;3:229-234. doi: 10.1016/s1470-2045(02)00714-3
  11. Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels G, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJ, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F. Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. Haematologica. 2002;87(12): 1258-1264. doi: 10.3816/clm.2009.n.074
  12. Savage KJ, Al-Rajhi N, Voss N, Paltiel C, Klasa R, Gascoyne RD, Connors JM. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006;17(1):122-130. doi: 10.1093/annonc/mdj030
  13. Aoki T, Izutsu K, Suzuki R, Nakaseko C, Arima H, Shimada K, Tomita A, Sasaki M, Takizawa J, Mitani K, Iqarashi T, Maeda Y, Fukuhara H, Ishida F, Niitsu N, OZhmachi K, Takasaki H, Nakamura N, Kinoshita T, Nakamura S, Oqura M. Prognostic significance of pleural or pericardial effusion and the implication of optimal treatment in primary mediastinal large B-cell lymphoma: multicenter retrospective study in Japan. Haematologica. 201499:1817-1825. doi: 10.3324/haematol.2014.111203
  14. Vassilakopoulos TP, Pangalis G, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, Dimopoulos MA, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012;17(2):239-249. doi: 10.1634/theoncologist.2011-027
  15. Мангасарова Я.К., Магомедова А.У., Кравченко С.К., Шмаков Р.Г., Барях Е.А., Воробьев В.И., Марьин Д.С., Скидан Н.И., Гемджян Э.Г., Мисюрин А.В., Кременецкая А.М., Воробьев А.И. Восьмилетний опыт лечения агрессивных В-крупноклеточных лимфом средостения. Терапевтический архив. 2013;7:50-56.
  16. Rieger M, Osterborg A, Pettengell R, White D, Gill D, Walewski J, Kuhnt E, Loefffler M, Pfeundschuh M, Ho AD. Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011;22(3):664-670. doi: 10.1093/annonc/mdq418
  17. Mazzarotto R, Boso C, Vianello F, Aversa MS, Chiarion-Sileni V, Trentin L, Zambello R, Muzzio PC, Fiore D, Sotti G. Primary mediastinal large B-cell lymphoma: results of intensive chemotherapy regimens (MACOP-B/VACOP-B) plus involved field radiotherapy on 53 patients. A single institution experience. Int J Radiat Oncol Biol Phys. 2007;68:823-829. doi: 10.1016/j.ijrobp.2006.12.048
  18. Todeschini G, Secchi S, Morra E, Vitolo U, Orlandi E, Pasini F, Gallo E, Amborosetti A, Tecchio C, Tarella C, Gabbas A, Gallamini A, Gargantini L, Pizzuti M, Fioritoni G, Gottin L, Rossi G, Lazzarino M, Menestrina F, Paulli M, Palestro M, Cabras MG, Di Vito F, Pizzolo G. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B. Br J Cancer. 2004;90(2):372-376. doi: 10.1016/j.ijrobp.2006.12.048
  19. Martelli MP, Martelli M, Pescarmona E. MACOP-B and involved field radiation therapy is an effective therapy for primary mediastinal large B-cell lymphoma with sclerosis. Ann Oncol. 1998;9:1027-1029.
  20. Bertini M, Orsucci L, Vitolo U, Levis A, Todeschini G, Meneghini V, Novero D, Tarella C, Gallo E, Luxi G, et al. Stage II large B-cell lymphoma with sclerosis treated with MACOP-B. Ann Oncol. 1991;2:733-737.
  21. Dunleavy K, Pittaluga S, Maeda L, Advani R, Chen CC, Hessler J, Steinberg SM, Grant C, Wright G, Varma G, Staudt LM, Jaffe ES, Wilson WH. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408-1416. doi: 10.1056/nejmoa1214561
  22. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329-1236. doi: 10.1080/10428190802108870
  23. Zinzani PL, Stefoni V, Finolezzi E, Brusamolino E, Cabras MG, Chiappella A, Salvi F, Rossi A, Broccoli A, Martelli M. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9(5):381-385. doi: 10.3816/CLM.2009.n.074
  24. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SL, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobianai K, Vose JM, Connors JM, Federico M, Deihl V. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol. 2007;25:579-586. doi: 10.1200/jco.2006.09.2403
  25. Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U, Stelitano C, Brusamolino E, Cabras MG, Rigacci L, Balzarotti M, Salvi F, Montoto S, Lopez-Guillermo A, Finolezzi E, Pileri SA, Daviees A, Cavalli F, Giovanella L, Johnson PW. [18F]Fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol. 2014;32(17):1769-1775. doi: 10.1200/jco.2013.51.7524
  26. Woessmann W, Lisfeld J, Burkhardt B. NHL-BFM Study Group. Therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;369(3):282. doi: 10.1056/NEJMc1305983
  27. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drobohlav N, Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld N, Staudt L, Cheson BD, Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8). doi: 10.1182/blood.v99.8.2685

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies